Table 2

Characteristics of ethylene-vinyl alcohol co-polymer studies

StudyNo of patientsMales (n (%))Study periodGrades I, II (%)Agent
Jahan et al43238 (34.8)1998–199930.4EVOH
FDA trial314620 (43.5)NA54.3EVOH
Joseph et al4452 (40)2004–2005NAEVOH
Leonardi et al45*3417 (50)NA0.0EVOH (all), (NBCA, coil in 1 patient)
Tevah et al.462411 (45.8)2004–2005NAEVOH (all), (NBCA in 2 patients)
Pierot et al474823 (47.9)2003–2005NAEVOH
Perez-Higueras et al74522 (48.9)1999–2004NAEVOH
Weber et al484731 (66)2002–200453.2EVOH
van Rooij et al134426 (59.1)2000–2005NAEVOH (all), (NBCA in 2 patients)
Katsaridis et al49§10158 (57.4)2004–200724.8EVOH (all), PVA (15.1%), NBCA (7.8%), coil (0.9%)
Velat et al402010 (50)2002–200675.0EVOH
Panagiotopoulos 68241 (50)2002–200872.0EVOH
Geo et al5011572 (62.6)2003–200733.0EVOH
Pan et al512014 (70)2006–200845.0EVOH
Loh et al415424 (44.4)2001–200353.7EVOH
Maimon et al52 ¶**4327 (62.8)2006–200718.6EVOH (all), NBCA in 3 patients
Abud et al53178 (47.1)2008–200947.1EVOH
Xu et al548651 (59.3)2004–200718.6EVOH
Saatci et al55††350206 (58.9)1999–200845.1EVOH (all), NBCA (12%)
van Rooij et al142417 (70.8)2008–201183.3EVOH
Jadadeesan et al5641 (25)2002–200425.0EVOH
  • In addition to EVOH, the following agents were used as a complementary agent(s):

  • *NBCA and coil were used in one case.

  • †NBCA was used in 2 cases.

  • ‡NBCA was used in 2 cases.

  • §Particle in 15.1%, NBCA in 7.8%, and coil in 0.9% of patients.

  • ¶Detachable tip (Sonic) was used.

  • **NBCA in 3 cases.

  • ††NBCA in 12% of patients.

  • EVOH, ethylene-vinyl alcohol co-polymer; NA, not available; NBCA, n-butyl cyanoacrylate; PVA, polyvinyl alcohol.